Parameter
| Biomarker | CD30 | Full name | Cluster of differentiation 30 | Molecular Type | Protein (transmembrane glycoprotein) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Targeted Therapy Targets |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Immunohistochemistry (IHC) | ||
| Pathobiological Mechanisms | Belongs to the tumor necrosis factor receptor superfamily, normally expressed in activated T cells, B cells, and NK cells; in CD30-positive Hodgkin lymphoma, tumor cells exhibit high expression of CD30, serving as a disease-specific marker. | ||||
| Clinical Availability Status | Clinical validation/guideline recommendation: It is the core biomarker for the diagnosis of CD30-positive Hodgkin lymphoma and also serves as a key target for anti-CD30 targeted therapy. | ||||
| Notes and Dynamics | The efficacy of anti-CD30 monoclonal antibodies (e.g., Brentuximab Vedotin) depends on the expression level of tumor cell CD30, and the expression status must be confirmed by immunohistochemistry (IHC) to guide the selection of targeted therapy regimens. | ||||